HLSQ

SEC source: 0001014108-22-000161 · primary_doc.xml · nonDerivative · entry 6

Ugwumba Chidozie · CIK 0001835544 · Exit Form 4 - former 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By SymBiosis, LLC

Disclosed balance after: 3,561,749

F1 · balance_after: The shares are directly held by SymBiosis, LLC.

SEC source: 0001014108-22-000161 · primary_doc.xml · nonDerivative · entry 5

Ugwumba Chidozie · CIK 0001835544 · Exit Form 4 - former 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By SymBiosis, LLC

Disclosed balance after: 3,583,084

F1 · balance_after: The shares are directly held by SymBiosis, LLC.

SEC source: 0001014108-22-000161 · primary_doc.xml · nonDerivative · entry 4

Ugwumba Chidozie · CIK 0001835544 · Exit Form 4 - former 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By SymBiosis, LLC

Disclosed balance after: 3,591,647

F1 · balance_after: The shares are directly held by SymBiosis, LLC.

SEC source: 0001014108-22-000161 · primary_doc.xml · nonDerivative · entry 3

Ugwumba Chidozie · CIK 0001835544 · Exit Form 4 - former 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Symbiosis, LLC

Disclosed balance after: 3,598,847

F1 · balance_after: The shares are directly held by SymBiosis, LLC.

SEC source: 0001014108-22-000161 · primary_doc.xml · nonDerivative · entry 2

Ugwumba Chidozie · CIK 0001835544 · Exit Form 4 - former 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Symbiosis, LLC

Disclosed balance after: 3,610,253

F1 · balance_after: The shares are directly held by SymBiosis, LLC.

SEC source: 0001014108-22-000161 · primary_doc.xml · nonDerivative · entry 1

Ugwumba Chidozie · CIK 0001835544 · Exit Form 4 - former 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By SymBiosis, LLC

Disclosed balance after: 3,620,077

F1 · balance_after: The shares are directly held by SymBiosis, LLC.

SEC source: 0001213900-22-016995 · ownership.xml · derivative · entry 1

Greig Russell · CIK 0001789914 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,000

Underlying: Common Stock · 41,000 shares

Expires 2032-03-29

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 29, 2023, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-22-016950 · ownership.xml · derivative · entry 1

Amusa Gbolahan · CIK 0001761120 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,500

Underlying: Common Stock · 20,500 shares

Expires 2032-03-29

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 29, 2023, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-22-016958 · ownership.xml · derivative · entry 1

GROSSMAN JONAS · CIK 0001423905 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,500

Underlying: Common Stock · 20,500 shares

Expires 2032-03-29

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 29, 2023, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-22-016980 · ownership.xml · derivative · entry 1

Sullivan Lynne Marie · CIK 0001727640 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,500

Underlying: Common Stock · 20,500 shares

Expires 2032-03-29

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 29, 2023, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-22-016991 · ownership.xml · derivative · entry 1

Moses Alan Charles · CIK 0001819501 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,500

Underlying: Common Stock · 20,500 shares

Expires 2032-03-29

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 29, 2023, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-22-016988 · ownership.xml · derivative · entry 1

Bassan Merav · CIK 0001792702 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2032-03-29

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 29, 2023, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-22-016986 · ownership.xml · derivative · entry 1

Wolfson Marina · CIK 0001797360 · SVP of Finance & Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2032-03-29

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 29, 2023, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-22-016969 · ownership.xml · derivative · entry 1

Solomon Jonathan Eitan · CIK 0001792322 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 205,000

Underlying: Common Stock · 205,000 shares

Expires 2032-03-29

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 29, 2023, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001014108-22-000058 · primary_doc.xml · derivative · entry 2

Walton Thomas Layton · CIK 0001840680 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By SymBiosis, LLC

Disclosed balance after: 0

Underlying: Common Stock · 1,875,000 shares

Expires 2027-01-28

F1 · kind: The common stock and warrants to purchase common stock previously reported by the reporting person are no longer indirectly beneficially owned by such reporting person and the reporting person specifically disclaims beneficial ownership of the securities reported. The shares are directly held by SymBiosis, LLC, over which the reporting person exercises investment discretion, but does not possess voting or dispositive power.

SEC source: 0001014108-22-000058 · primary_doc.xml · nonDerivative · entry 1

Walton Thomas Layton · CIK 0001840680 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By SymBiosis, LLC

Disclosed balance after: 0

F1 · kind: The common stock and warrants to purchase common stock previously reported by the reporting person are no longer indirectly beneficially owned by such reporting person and the reporting person specifically disclaims beneficial ownership of the securities reported. The shares are directly held by SymBiosis, LLC, over which the reporting person exercises investment discretion, but does not possess voting or dispositive power.

SEC source: 0001213900-21-039435 · ownership.xml · derivative · entry 2

Greig Russell · CIK 0001789914 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,813

Underlying: Common Stock · 2,813 shares

Expires 2027-01-28

F1 · price: The common stock and common stock warrant were acquired in the issuer's registered direct offering of units, in which each unit consisted of one share of common stock and one common stock warrant to purchase 0.75 of a share of common stock, at a price of $4.00 per unit. The price paid per unit is reflected in Table I.

F2 · derivative.exercise_date: The common stock warrant will be exercisable six months after the date of issuance, at an exercise price of $5.00 per share and will expire five years from the date such warrant first becomes exercisable.

F3 · ownership.nature: The common stock and common stock warrant are held by Greig Biotechnology Global Consulting Inc.; Mr. Greig, as the sole director, an officer and the controlling shareholder of Greig Biotechnology Global Consulting Inc., may be deemed to be a beneficial owner of these shares, but Mr. Greig disclaims such beneficial ownership except to the extent of his pecuniary interest therein.

SEC source: 0001213900-21-039435 · ownership.xml · nonDerivative · entry 1

Greig Russell · CIK 0001789914 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,750

F1 · price: The common stock and common stock warrant were acquired in the issuer's registered direct offering of units, in which each unit consisted of one share of common stock and one common stock warrant to purchase 0.75 of a share of common stock, at a price of $4.00 per unit. The price paid per unit is reflected in Table I.

F3 · ownership.nature: The common stock and common stock warrant are held by Greig Biotechnology Global Consulting Inc.; Mr. Greig, as the sole director, an officer and the controlling shareholder of Greig Biotechnology Global Consulting Inc., may be deemed to be a beneficial owner of these shares, but Mr. Greig disclaims such beneficial ownership except to the extent of his pecuniary interest therein.

SEC source: 0001213900-21-039433 · ownership.xml · derivative · entry 2

SEKHRI PAUL J · CIK 0001264519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,375

Underlying: Common Stock · 9,375 shares

Expires 2027-01-28

F1 · price: The common stock and common stock warrant were acquired in the issuer's registered direct offering of units, in which each unit consisted of one share of common stock and one common stock warrant to purchase 0.75 of a share of common stock, at a price of $4.00 per unit. The price paid per unit is reflected in Table I.

F2 · derivative.exercise_date: The common stock warrant will be exercisable six months after the date of issuance, at an exercise price of $5.00 per share and will expire five years from the date such warrant first becomes exercisable.

SEC source: 0001213900-21-039433 · ownership.xml · nonDerivative · entry 1

SEKHRI PAUL J · CIK 0001264519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

F1 · price: The common stock and common stock warrant were acquired in the issuer's registered direct offering of units, in which each unit consisted of one share of common stock and one common stock warrant to purchase 0.75 of a share of common stock, at a price of $4.00 per unit. The price paid per unit is reflected in Table I.

SEC source: 0000947871-21-000844 · ownership.xml · derivative · entry 2

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · 10% owner

OrbiMed Israel GP Ltd. · CIK 0001569590 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 375,000

Underlying: Common Stock · 375,000 shares

Expires 2027-01-28

F1 · price: In the Issuer's underwritten public offering, OrbiMed Israel Partners Limited Partnership ("OIP") purchased units that included 500,000 shares of the Issuer's common stock and 375,000 warrants, each exercisable for 1 share of the Issuer's common stock. The purchase price of each unit was $4.00.

F1 · ownership.nature: In the Issuer's underwritten public offering, OrbiMed Israel Partners Limited Partnership ("OIP") purchased units that included 500,000 shares of the Issuer's common stock and 375,000 warrants, each exercisable for 1 share of the Issuer's common stock. The purchase price of each unit was $4.00.

F2 · ownership.nature: The purchase reported on this Form 4 were made by OIP. Following the transactions reported on this Form 4, OIP LP is the direct owner of 2,172,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership ("OII") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund"), which is the general partner of OIP and OII. By virtue of these relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and OII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon, Nissim Darvish, Anat Naschitz, and Erez Chimovits.

F3 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-21-000844 · ownership.xml · nonDerivative · entry 1

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · 10% owner

OrbiMed Israel GP Ltd. · CIK 0001569590 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,813,489

F1 · shares: In the Issuer's underwritten public offering, OrbiMed Israel Partners Limited Partnership ("OIP") purchased units that included 500,000 shares of the Issuer's common stock and 375,000 warrants, each exercisable for 1 share of the Issuer's common stock. The purchase price of each unit was $4.00.

F1 · price: In the Issuer's underwritten public offering, OrbiMed Israel Partners Limited Partnership ("OIP") purchased units that included 500,000 shares of the Issuer's common stock and 375,000 warrants, each exercisable for 1 share of the Issuer's common stock. The purchase price of each unit was $4.00.

F1 · ownership.nature: In the Issuer's underwritten public offering, OrbiMed Israel Partners Limited Partnership ("OIP") purchased units that included 500,000 shares of the Issuer's common stock and 375,000 warrants, each exercisable for 1 share of the Issuer's common stock. The purchase price of each unit was $4.00.

F2 · ownership.nature: The purchase reported on this Form 4 were made by OIP. Following the transactions reported on this Form 4, OIP LP is the direct owner of 2,172,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership ("OII") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund"), which is the general partner of OIP and OII. By virtue of these relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and OII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon, Nissim Darvish, Anat Naschitz, and Erez Chimovits.

F3 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001213900-21-039439 · ownership.xml · derivative · entry 2

Sullivan Lynne Marie · CIK 0001727640 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,375

Underlying: Common Stock · 9,375 shares

Expires 2027-01-28

F1 · price: The common stock and common stock warrant were acquired in the issuer's registered direct offering of units, in which each unit consisted of one share of common stock and one common stock warrant to purchase 0.75 of a share of common stock, at a price of $4.00 per unit. The price paid per unit is reflected in Table I.

F2 · derivative.exercise_date: The common stock warrant will be exercisable six months after the date of issuance, at an exercise price of $5.00 per share and will expire five years from the date such warrant first becomes exercisable.

SEC source: 0001213900-21-039439 · ownership.xml · nonDerivative · entry 1

Sullivan Lynne Marie · CIK 0001727640 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

F1 · price: The common stock and common stock warrant were acquired in the issuer's registered direct offering of units, in which each unit consisted of one share of common stock and one common stock warrant to purchase 0.75 of a share of common stock, at a price of $4.00 per unit. The price paid per unit is reflected in Table I.

SEC source: 0001213900-21-039441 · ownership.xml · derivative · entry 2

Wolfson Marina · CIK 0001797360 · SVP of Finance & Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,813

Underlying: Common Stock · 2,813 shares

Expires 2027-01-28

F1 · price: The common stock and common stock warrant were acquired in the issuer's registered direct offering of units, in which each unit consisted of one share of common stock and one common stock warrant to purchase 0.75 of a share of common stock, at a price of $4.00 per unit. The price paid per unit is reflected in Table I.

F2 · derivative.exercise_date: The common stock warrant will be exercisable six months after the date of issuance, at an exercise price of $5.00 per share and will expire five years from the date such warrant first becomes exercisable.

SEC source: 0001213900-21-039441 · ownership.xml · nonDerivative · entry 1

Wolfson Marina · CIK 0001797360 · SVP of Finance & Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,750

F1 · price: The common stock and common stock warrant were acquired in the issuer's registered direct offering of units, in which each unit consisted of one share of common stock and one common stock warrant to purchase 0.75 of a share of common stock, at a price of $4.00 per unit. The price paid per unit is reflected in Table I.

SEC source: 0001213900-21-039437 · ownership.xml · derivative · entry 2

Solomon Jonathan Eitan · CIK 0001792322 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,750

Underlying: Common Stock · 18,750 shares

Expires 2027-01-28

F1 · price: The common stock and common stock warrant were acquired in the issuer's registered direct offering of units, in which each unit consisted of one share of common stock and one common stock warrant to purchase 0.75 of a share of common stock, at a price of $4.00 per unit. The price paid per unit is reflected in Table I.

F2 · derivative.exercise_date: The common stock warrant will be exercisable six months after the date of issuance, at an exercise price of $5.00 per share and will expire five years from the date such warrant first becomes exercisable.

SEC source: 0001213900-21-039437 · ownership.xml · nonDerivative · entry 1

Solomon Jonathan Eitan · CIK 0001792322 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

F1 · price: The common stock and common stock warrant were acquired in the issuer's registered direct offering of units, in which each unit consisted of one share of common stock and one common stock warrant to purchase 0.75 of a share of common stock, at a price of $4.00 per unit. The price paid per unit is reflected in Table I.

SEC source: 0001213900-21-039431 · ownership.xml · derivative · entry 2

Moses Alan Charles · CIK 0001819501 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,750

Underlying: Common Stock · 3,750 shares

Expires 2027-01-28

F1 · price: The common stock and common stock warrant were acquired in the issuer's registered direct offering of units, in which each unit consisted of one share of common stock and one common stock warrant to purchase 0.75 of a share of common stock, at a price of $4.00 per unit. The price paid per unit is reflected in Table I.

F2 · derivative.exercise_date: The common stock warrant will be exercisable six months after the date of issuance, at an exercise price of $5.00 per share and will expire five years from the date such warrant first becomes exercisable.

SEC source: 0001213900-21-039431 · ownership.xml · nonDerivative · entry 1

Moses Alan Charles · CIK 0001819501 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F1 · price: The common stock and common stock warrant were acquired in the issuer's registered direct offering of units, in which each unit consisted of one share of common stock and one common stock warrant to purchase 0.75 of a share of common stock, at a price of $4.00 per unit. The price paid per unit is reflected in Table I.

SEC source: 0001213900-21-039168 · ownership.xml · derivative · entry 2

Amusa Gbolahan · CIK 0001761120 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,750

Underlying: Common Stock · 18,750 shares

Expires 2027-01-28

F1 · price: The reporting person acquired 25,000 units consisting of one share of common stock and three-quarters of one warrant at a purchase price of $4.00 per unit.

SEC source: 0001213900-21-039168 · ownership.xml · nonDerivative · entry 1

Amusa Gbolahan · CIK 0001761120 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 262,871

F1 · price: The reporting person acquired 25,000 units consisting of one share of common stock and three-quarters of one warrant at a purchase price of $4.00 per unit.

SEC source: 0001213900-21-039171 · ownership.xml · derivative · entry 2

GROSSMAN JONAS · CIK 0001423905 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,125

Underlying: Common Stock · 28,125 shares

Expires 2027-01-28

F1 · price: The reporting person acquired 37,500 units consisting of one share of common stock and three-quarters of one warrant at a purchase price of $4.00 per unit.

SEC source: 0001213900-21-039171 · ownership.xml · nonDerivative · entry 1

GROSSMAN JONAS · CIK 0001423905 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 372,217

F1 · price: The reporting person acquired 37,500 units consisting of one share of common stock and three-quarters of one warrant at a purchase price of $4.00 per unit.

SEC source: 0001213900-21-043458 · ownership.xml · nonDerivative · entry 1

GROSSMAN JONAS · CIK 0001423905 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 372,717

F1 · price: The reporting person acquired 37,500 units consisting of one share of common stock and three-quarters of one warrant at a purchase price of $4.00 per unit.

F2 · balance_after: This number was originally reported as 372,217, as opposed to 372,717. This amendment is being filed to correct that typographical error.

SEC source: 0001213900-21-019697 · ownership.xml · derivative · entry 1

Greig Russell · CIK 0001789914 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,400

Underlying: Common Stock · 30,400 shares

Expires 2031-03-30

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 30, 2022, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-21-019653 · ownership.xml · derivative · entry 1

Amusa Gbolahan · CIK 0001761120 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,200

Underlying: Common Stock · 15,200 shares

Expires 2031-03-30

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 30, 2022, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-21-019656 · ownership.xml · derivative · entry 1

GROSSMAN JONAS · CIK 0001423905 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,200

Underlying: Common Stock · 15,200 shares

Expires 2031-03-30

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 30, 2022, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-21-019689 · ownership.xml · derivative · entry 1

SEKHRI PAUL J · CIK 0001264519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,200

Underlying: Common Stock · 15,200 shares

Expires 2031-03-30

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 30, 2022, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-21-019664 · ownership.xml · derivative · entry 1

Sullivan Lynne Marie · CIK 0001727640 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,200

Underlying: Common Stock · 15,200 shares

Expires 2031-03-30

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 30, 2022, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-21-019700 · ownership.xml · derivative · entry 1

Puttagunta Sailaja · CIK 0001792314 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,250

Underlying: Common Stock · 71,250 shares

Expires 2031-03-30

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 30, 2022, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-21-019683 · ownership.xml · derivative · entry 1

Moses Alan Charles · CIK 0001819501 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,200

Underlying: Common Stock · 15,200 shares

Expires 2031-03-30

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 30, 2022, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-21-019685 · ownership.xml · derivative · entry 1

Oron Assaf · CIK 0001792310 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,250

Underlying: Common Stock · 33,250 shares

Expires 2031-03-30

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 30, 2022, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-21-019678 · ownership.xml · derivative · entry 1

Bassan Merav · CIK 0001792702 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,500

Underlying: Common Stock · 47,500 shares

Expires 2031-03-30

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 30, 2022, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-21-019670 · ownership.xml · derivative · entry 1

Wolfson Marina · CIK 0001797360 · SVP of Finance & Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,250

Underlying: Common Stock · 33,250 shares

Expires 2031-03-30

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 30, 2022, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-21-019660 · ownership.xml · derivative · entry 1

Solomon Jonathan Eitan · CIK 0001792322 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 152,000

Underlying: Common Stock · 152,000 shares

Expires 2031-03-30

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 30, 2022, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-20-030126 · ownership.xml · derivative · entry 1

SEKHRI PAUL J · CIK 0001264519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2030-10-02

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on October 2, 2021, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-20-030124 · ownership.xml · derivative · entry 1

Moses Alan Charles · CIK 0001819501 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2030-10-02

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on October 2, 2021, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-21-043458 · ownership.xml · derivative · entry 2

GROSSMAN JONAS · CIK 0001423905 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,125

Underlying: Common Stock · 28,125 shares

Expires 2027-01-28

F1 · price: The reporting person acquired 37,500 units consisting of one share of common stock and three-quarters of one warrant at a purchase price of $4.00 per unit.

SEC source: 0001213900-20-018301 · ownership.xml · derivative · entry 3

GROSSMAN JONAS · CIK 0001423905 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 716,439

Underlying: Common Stock · 666,310 shares

Expires 2024-10-28

F1 · kind: The shares were distributed to the reporting person by Mountain Wood LLC, which distributed its securities in the issuer to its members.

F1 · price: The shares were distributed to the reporting person by Mountain Wood LLC, which distributed its securities in the issuer to its members.